Paper6991941
Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens.
Woods RL and 4 others. N Engl J Med, 1980. Cited by 132 papers, by iCite.
Cite this record
ConductScience Library. Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. Papers, record 6991941. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6991941
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Antineoplastic Agents | Major topic |
| Adult | |
| Aged | |
| Bone Neoplasms | |
| Clinical Trials as Topic | |
| Cyclophosphamide | |
| Doxorubicin | |
| Drug Therapy, Combination | |
| Female | |
| Fluorouracil | |
| Humans | |
| Liver Neoplasms | |
| Lung Neoplasms | |
| Male | |
| Methotrexate | |
| Middle Aged | |
| Mitomycins | |
| Random Allocation |
Source PubMed
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 132 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40242159 | Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40242159 | PubMed |
| 22048624 | Carcinomas of an unknown primary origin--diagnosis and treatment. | Nat Rev Clin Oncol | 2011 | https://conductscience.org/library/papers/22048624 | PubMed |
| 20824034 | Carcinoma of Unknown Primary - an Orphan Disease? | Breast Care (Basel) | 2008 | https://conductscience.org/library/papers/20824034 | PubMed |
| 20300978 | Gemcitabine and cisplatin in patients with carcinoma of unknown primary site. | Med Oncol | 2011 | https://conductscience.org/library/papers/20300978 | PubMed |
| 19623297 | Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome. | Dtsch Arztebl Int | 2008 | https://conductscience.org/library/papers/19623297 | PubMed |
| 12647637 | Adenocarcinoma of unknown primary site. | Korean J Intern Med | 2002 | https://conductscience.org/library/papers/12647637 | PubMed |
| 8795590 | How should cancer presenting as a malignant pleural effusion be managed? | Br J Cancer | 1996 | https://conductscience.org/library/papers/8795590 | PubMed |
| 8601568 | The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary. | J Cancer Res Clin Oncol | 1996 | https://conductscience.org/library/papers/8601568 | PubMed |
| 3933808 | Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin. | CMAJ | 1985 | https://conductscience.org/library/papers/3933808 | PubMed |
| 3791561 | Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3791561 | PubMed |
| 2491794 | Phase II study of combination 4'-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2491794 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6991941
GET https://conductscience.org/api/papers/v1/6991941/authors